Immuneering (IMRX) Morgan Stanley 22nd Annual Global Healthcare Conference summary

Company overview and strategy

• Focused on developing therapies that provide durable, complete responses for cancer patients, addressing cancer's adaptability and ability to hide among healthy cells.

• Pipeline designed to selectively target malignant cells and block multiple escape pathways, with IMM-1-104 as the lead program.

• Emphasizes the importance of drug tolerability to enable combination therapies and broader treatment opportunities.

• Pursuing both monotherapy and combination strategies, with a strong interest in earlier lines of therapy.

• Maintains a robust preclinical pipeline and is exploring additional programs beyond current clinical candidates.

Clinical and preclinical data highlights

• IMM-1-104 phase I results showed strong tolerability, with minimal high-grade adverse events and favorable comparison to other MAP kinase pathway inhibitors.

• No acquired RAS gene alterations observed in ctDNA, suggesting broad pathway blockade and reduced tumor escape via common resistance mutations.

• Shrinking lesions observed in about half of phase I patients, including significant responses in late-line pancreatic cancer.

• Preclinical data demonstrated durable tumor growth inhibition when combining IMM-1-104 with standard chemotherapies in animal models.

• 415, the second clinical program, uses a similar deep cyclic inhibition approach with a shorter half-life, targeting both RAS and RAF mutations.

Ongoing and future clinical development

• Phase II-A for IMM-1-104 includes five arms, with two combination arms in first-line pancreatic cancer using standard chemotherapies.

• Data from multiple phase II-A arms expected this year, with clear benchmarks for efficacy and tolerability based on standard of care.

• 415 phase I/II-A study is ongoing, with endpoints focused on safety, PK, and PD; data expected by year-end.

• Future phase II-A for 415 will likely explore multiple tumor types, especially those with strong preclinical data such as pancreatic, melanoma, lung, and colorectal cancers.

• Interest remains high in exploring colorectal cancer and immuno-oncology combinations, though not all are included in current trials.